FDP/FIB ratio serves as a novel biomarker for diagnosing bone marrow invasion in gastric cancer and predicting patient prognosis\

  • 0Department of Clinical Laboratory, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

|

|

Summary

This summary is machine-generated.

The Fibrinogen Degradation Products/Fibrinogen (FDP/FIB) ratio is a key indicator for diagnosing bone marrow invasion in gastric cancer. A high FDP/FIB ratio signifies poorer prognosis and shorter survival in stage IV gastric cancer patients.

Area Of Science

  • Oncology
  • Hematology
  • Medical Diagnostics

Background

  • Gastric cancer bone marrow invasion is a critical factor influencing patient prognosis.
  • Identifying reliable laboratory markers for bone marrow invasion is essential for effective treatment strategies.

Purpose Of The Study

  • To identify laboratory indicators for bone marrow invasion in gastric cancer.
  • To evaluate the prognostic value of these indicators, particularly the FDP/FIB ratio.

Main Methods

  • Retrospective analysis of 320 gastric cancer patients' clinical data.
  • Comparison of laboratory markers between patients with and without bone marrow invasion.
  • Receiver operating characteristic (ROC) curve analysis and survival analysis (Kaplan-Meier, Cox regression).

Main Results

  • The FDP/FIB ratio, along with other markers (Hb, PLT, CEA, CA72-4, etc.), showed significant differences between groups (P < 0.05).
  • ROC analysis identified FDP/FIB ratio (AUC = 0.958) as a strong predictor of bone marrow invasion.
  • High FDP/FIB ratio was associated with significantly shorter survival in stage IV gastric cancer patients (P < 0.001).
  • Bone marrow invasion and FDP/FIB ratio were independent risk factors for prognosis (HR = 4.148, P = 0.020 and HR = 1.026, P = 0.024, respectively).

Conclusions

  • The FDP/FIB ratio is a valuable diagnostic indicator for gastric cancer bone marrow invasion.
  • Elevated FDP/FIB ratio serves as an independent prognostic factor for survival in gastric cancer patients with bone marrow invasion.